Global Arthritis Therapeutics Market

1. Summary

The Global Arthritis Therapeutics Market was valued at $30.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.5% CAGR, to an estimated market size of $41.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global arthritis therapeutics market encompasses the development and commercialization of pharmaceuticals and biopharmaceuticals specifically designed to manage autoimmune and inflammatory joint conditions, primarily rheumatoid arthritis and osteoarthritis. The scope includes biologics, disease-modifying anti-rheumatic drugs (DMARDs), JAK inhibitors, and NSAIDs, while excluding orthopedic surgical implants and general physical therapy services.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Arthritis Therapeutics Market in the period 2025-30:

• The rising global prevalence of autoimmune disorders is driven by an aging population and sedentary lifestyles, creating a sustained demand for long-term maintenance therapies.
• There is a significant shift toward personalized medicine, with treatments increasingly tailored to individual patient genetic profiles and disease severity.
• The rapid market entry of biosimilars is increasing treatment accessibility while simultaneously putting downward pressure on the pricing of original reference biologics.
• The adoption of JAK inhibitors is growing as a preferred oral alternative to traditional injectable biologics for patients seeking more convenient administration routes.
• Integration of digital health solutions, including wearable sensors and mobile apps, is improving patient engagement and real-time monitoring of disease progression.
• Increased R&D investment is focusing on novel therapeutic pathways and 'treat-to-target' strategies to achieve clinical remission rather than just symptom management.
• Strategic M&A activity and alliances between pharmaceutical giants and biotech startups are accelerating the clinical pipeline for next-generation monoclonal antibodies.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: